Avitus™ Orthopaedics
Avitus™ Orthopaedics, Inc. was established in 2011 with the mission of developing new orthopaedic technologies that improve clinical outcomes while decreasing health care costs. The company is developing a novel surgical device that will enable surgeons to use autologous bone graft material to improve the lives of patients. Avitus is currently looking to close their Series A round.
Company Overview
| Founded Year | 2011 |
| Location | Farmington, CT |
| Founders | Maxim Budyansky
Neil Shah |
Bastion Health
Bastion Health is a digital health platform pioneering technology to impact and enhance male reproductive health and prostate health. Found on the belief that healthcare should be accessible, affordable, and comprehensive, Bastion created at-home testing kits for men.
Company Overview
| Founded Year | 2018 |
| Location | Farmington, CT |
| Founders | Reza Amin
Khashayar Dashti |
Biorasis
Biorasis, Inc. is a privately held company committed to developing a wireless, needle-implantable (0.5 x 0.5 x 5 mm) biosensor platform for real time, continuous metabolite monitoring. Based at UConn's Technology Incubation Program, Biorasis is a faculty-owned startup.
Company Overview
| Founded Year | 2007 |
| Location | Mansfield, CT |
| Founders | Faquir Jain
Fotios Papadimitrakopoulos |
Cornovus Pharmaceuticals
Cornovus Pharmaceuticals, Inc. commenced operations in October of 2011. The company is focused on the development of a novel cardioprotective compound, MRS2339, for the treatment of heart failure. MRS2339 is a small molecule that stimulates cardiac myocyte P2X4 receptors, which in turn increases myocyte eNOS and cGMP. The compound has been shown effective in multiple preclinical models of heart failure and currently is progressing through IND enabling studies.
Company Overview
| Founded Year | 2019 |
| Location | Farmington, CT |
| Founders | Bruce Liang |
Eir Medical Devices
Eir Medical Devices developed a device designed to help physicians measure patients’ blood viscosity, a traditionally unused, but promising indicator of cardiac risk and health for patients on dialysis and certain types of cancers.
Company Overview
| Founded Year | |
| Location | |
| Founders |
Encapsulate
Encapsulate BioChip technology grows patient-derived cancer cells ex vivo, and screens them against chemotherapeutic drugs. With this technology the oncologist can choose the most effective chemotherapy drug prior to treatment on an individualized basis.
Company Overview
| Founded Year | 2018 |
| Location | Farmington, CT |
| Founders | Armin Tahmasbi Rad
Leila Daneshmandi |
Genesist
Genesist with the help of evolutionary biology empowers the local and healthy cells around a cancerous tumor to stop cancer from metastasis and invasion. A CRISPR-based therapy to make stromal cells more resistant to cancer.
Company Overview
| Founded Year | 2022 |
| Location | Farmington, CT |
| Founders | Ashkan Novin Kshitiz |
Hans Health
Hans Health's platform technology, known as a Genomics Driven Immunoproteomics or GDI, allows rapid identification of personalized tumor mutation profiles that are recognized by cancer patients’ own immune system. This new immune assessment tool has the potential to offer more effective treatment options for some of the most aggressive cancer cases.
Company Overview
| Founded Year | 2018 |
| Location | West Hartford, CT |
| Founders | David Han |
LambdaVision
LambdaVision, Inc. (LVI) is developing a high-resolution, protein-based retinal implant to restore vision to the millions of patients blinded by retinal degenerative diseases, including retinitis pigmentosa (RP) and age-related macular degeneration (AMD). Based on a UConn chemistry discovery, the patent-protected retinal implant technology developed by LambdaVision uses the light-activated protein, bacteriorhodopsin, to replace the function of the damaged photoreceptor cells. The flexible, subretinal implant is powered by incident light and does not require any external power supplies or bulky hardware on or outside the eye, and offers the potential for far greater resolution than competing electrode-based technologies. LambdaVision, whose CEO is a UConn alumna, is currently at the pre-seed stage, but is looking for seed money to support further preclinical development.
Company Overview
| Founded Year | 2009 |
| Location | Farmington, CT |
| Founders | Robert Birge |
Lipid Genomics
Lipid Genomics is developing its FDA-approved investigational drug targeted at people with variations in the HDL ("good cholesterol") SCARB1 gene. More than 117 million people in the U.S. could benefit from this drug. Lipid Genomics has a potential to generate a very sizable profit as the market size for this therapeutic is $2.8 billion and the market size for their second product, novel immune checkpoint inhibitor lymphocyte activation gene-3 (LAG-3), is $1.4 billion.
Company Overview
| Founded Year | 2012 |
| Location | Farmington, CT |
| Founders | Dr. Annabelle Rodriguez |
Potentiometric Probes
Potentiometric Probes develops voltage-sensitive dye (VSD) technology for neuroscience and cardiac research. The company’s founders have a long history of developing VSDs and invented early classic VSDs such as Di-4-ANEPPS. But much has changed since the introduction of Di-4-ANEPPS (details below) and Potentiometric Probes is focused on providing researchers the best VSDs on the market in terms of signal-to-noise ratio, speed, stability, toxicity, among other factors.
Company Overview
| Founded Year | 2017 |
| Location | Farmington, CT |
| Founders | Leslie Loew Corey Acker Ping Yan |
SedMed
SedMed is a mobility products company that improves the safety & independence of those who struggle with Activities of Daily Living and reduces injuries to health care workers.
Company Overview
| Founded Year | 2020 |
| Location | Farmington, CT |
| Founders | Timothy Krupski
Jeremy Bronen |
Thetis Pharmaceuticals
Thetis Pharmaceuticals LLC is developing novel drugs to treat inflammation-related gastrointestinal diseases with high unmet medical needs. The lead candidate, TP-252, is rapidly advancing through pre-clinical evaluations with the goal of beginning clinical FDA studies in 2018. Thetis aims to partner with a large pharmaceutical company to bring TP-252 to market by 2023.
Company Overview
| Founded Year | 2011 |
| Location | Ridgefield, CT |
| Founders | Frank Sciavolino Gary Mathias |
Torigen Pharmaceuticals
Torigen Pharmaceuticals, Inc. has developed a treatment that can work for multiple tumor indications, treating more than 2 million companion animals diagnosed with cancer each year. Its product, VetiVax, is a novel, personalized immunotherapy that uses the animals’ own tumor cells to fight cancer. When combined with an innovative bulking agent, MIMTM (Matrix Immune Modulator), an overall reduction in tumor size and inhibition of metastasis have been noted. The treatment has been proven safe in a Phase I trial.
Company Overview
| Founded Year | 2013 |
| Location | Farmington, CT |
| Founders | Ashley Kalinauskas |